Hematopoietic Recovery and Priming — Therapeutic Effects of GM-CSF in the Treatment of AML
After a first study showed that GM-CSF following chemotherapy effectively accelerated neutrophil recovery and reduced early mortality in high risk patients with AML, a second study was begun in which GM-CSF was applied preceeding chemotherapy and continuing until neutrophil recovery in the initial 5 chemotherapy courses for patients with newly diagnosed AML. The CR rate in patients of 16–75 (median 50) years is 79% in GM-CSF patients and 82% in controls. GM-CSF patients showed a trend to more frequent rapid blast clearance and fewer persistent leukemias and — in patients under age 60 — a significantly superior remission duration as of this update. It should be shown later by this study whether GM-CSF multiple course priming and longterm administration adds to the cure rate of patients with AML.
KeywordsAcute Myeloid Leukemia Acute Myelogenous Leukemia Leukemic Blast Acute Myeloblastic Leukemia Remission Duration
Unable to display preview. Download preview PDF.
- 3.Rowe JM, Andersen J, Mazza JJ et al. (1993) Phase III randomized placebo-controlled study of granulocyte-macrophage colony stimulating factor (GM-CSF) in adult patients (55–70 years) with acute myelogenous leukemia (AML). A study of the Eastern Cooperative Oncology Group (ECOG). Blood 82 (1): 1299Google Scholar
- 4.Stone R, George S, Berg D et al. (1994) GM-CSF ‘V’ placebo during remission induction for patients > 60 years old with de novo acute myeloid leukemia: CALGB study #8923. Proc ASCO 13: 992Google Scholar
- 7.Kelleher C, Miyauchi J, Wong G et al. (1987) Synergism between recombinant growth factors GM-CSF and G-CSF, acting on the blast cells of acute myeloblastic leukemia. Blood 69: 1489–1503Google Scholar
- 13.Estey EH, Thall PF, Kantarjian H et al. (1992) Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: Comparison to patients treated without GM-CSF. Blood 79: 2246–2255PubMedGoogle Scholar
- 18.Büchner T, Hiddemann W, Löffler G et al. (1991) Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: Data from the AML Cooperative Group. Sem Hematol 28 (4): 76–79Google Scholar